{"Clinical Trial ID": "NCT00322348", "Intervention": ["INTERVENTION 1:", "ZOLADEX 10.8 mg", "ZOLADEX (goserelin acetate) 10.8 mg intramuscular deposition for injection every 12 weeks", "INTERVENTION 2:", "ZOLADEX 3.6 mg", "ZOLADEX (goserelin acetate) 3.6 mg intramuscular deposition for injection every 4 weeks"], "Eligibility": ["Incorporation criteria:", "Premenopausal women 18 years of age or older with positive breast cancer (ER +ve) histologically/cytologically confirmed", "World Health Organization (WHO) rate of return 0, 1, or 2", "Informed written consent", "- Exclusion criteria:", "Treatment with tamoxifen or other hormonal treatments as an early adjuvant of breast cancer (ECB) in the previous 24 weeks", "Has received radiation therapy in the last 4 weeks", "\u2022 History of systemic malignancy other than breast cancer in the previous 3 years", "Estimated survival less than 24 weeks"], "Results": ["Performance measures:", "Percentage of participants with progression-free survival (PFS) at week 24", "The number of participants for whom neither the objective progression of the disease nor the death (due to any cause) were observed at week 24 on the number of participants randomized x 100.", "Time: Evaluations of objective tumours performed every 12 weeks (+/- 7 days) until week 24, then every 24 weeks (+/- 14 days) until week 96 or objective progression is confirmed according to the criteria for evaluation of response in solid tumours (RECIST).", "Results 1:", "Title of arm/group: ZOLADEX 10,8 mg", "Description of the arm/group: ZOLADEX (goserelin acetate) 10.8 mg intramuscular deposition for injection every 12 weeks", "Total number of participants analysed: 49", "Type of measurement: Number", "Unit of measure: percentage of participants 69.4", "Results 2:", "Title of arm/group: ZOLADEX 3.6 mg", "Description of the arm/group: ZOLADEX (goserelin acetate) 3.6 mg intramuscular deposition for injection every 4 weeks", "Total number of participants analysed: 49", "Type of measurement: Number", "Unit of measure: percentage of participants 73.5"], "Adverse Events": ["Undesirable Events 1:", "Total: 2/50 (4.0 per cent)", "- Peritonillary abscess 0/50 (0.00 %)", "Fracture of the humerus 1/50 (2.0%)", "\u2022 Endometrial hyperplasia 1/50 (2.0%)", "Hematoma 0/50 (0.00 %)", "Adverse Events 2:", "Total: 3/48 (6.25 per cent)", "1/48 (2.08%)", "Fracture of the humerus 0/48 (0.00 %)", "Endometrial hyperplasia 1/48 (2.08%)", "Hematoma 1/48 (2.08%)"]}